Posters

      Systems Toxicology Assessment of Aerosol from a Candidate Modified Risk Tobacco Product Compared with Cigarette Smoke on Organotypic Gingival Epithelial Cultures

      Zanetti, F.; Titz, B.; Sewer, A.; Lo Sasso, G.; Scotti, E.; Schlage, W. K.; Mathis, C.; Leroy, P.; Majeed, S.; Ortega Torres, L.; Keppler, B. R.; Elamin, A.; Trivedi, K.; Guedj, E.; Martin, F.; Frentzel, S.; Ivanov, N. V.; Peitsch, M. C.; Hoeng, J.

      Conference date
      Jun 28, 2017
      Conference name
      19th International Conference on Oxidative Stress Reduction, Redox Homeostasis and Antioxidants
      Link to more information
      Link to more information
      Topic
      Summary

      No abstract available.

      Related Publications

      Systems Toxicology Approach For The Biological Impact Assessment Of Conventional Cigarette Smoke Fractions And Aerosol Fractions From A Prototypic Modified Risk Tobacco Product On Normal Human Bronchial Epithelial Cells

      Aerosol Chemistry Systems Toxicology

      Screening Of Aqueous Media Using GC×GC-TOF-MS

      Aerosol Chemistry Systems Toxicology

      Systems Toxicology Assessment of Repeated Exposure to Cigarette Smoke and a Candidate Modified-Risk Tobacco Product Aerosol on Gingival Organotypic Cultures

      Aerosol Chemistry Systems Toxicology

      Aerosol from a candidate modified risk tobacco product has reduced effects on chemotaxis and transendothelial migration compared to smoke from conventional cigarettes

      Aerosol Chemistry Systems Toxicology

      Characterization of Aerosol Exposure, Metabolism and Pharmacokinetics for Toxicological Assessment Using In Vitro Organotypical Airway Models

      Aerosol Chemistry Systems Toxicology

      In Vitro Toxicological Assessment Of Total Particulate Matter Of Tobacco Smoke And A pMRTP Aerosol In Human Lung Epithelial And Coronary Endothelial Cells

      Aerosol Chemistry Systems Toxicology

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.